Prognostic value of postoperative CEA/CA19-9 positivity and elevation relative to preoperative levels in gastric cancer

Table 1 Demographic and clinicopathologic characteristics of patients, n (%)

Variables	Patients (n = 562)
Sex
Male	385 (68.5)
Female	177 (31.5)
Age, years
< 60	248 (44.1)
≥ 60	314 (55.9)
Clinical stage (pTNM)
I	61 (10.8)
II	169 (30.1)
III	332 (59.1)
T stage
T1	45 (8)
T2	63 (11.2)
T3	117 (20.8)
T4	337 (60)
N stage
N0	151 (26.9)
N1	108 (19.2)
N2	146 (26)
N3	157 (27.9)
Differentiation
Good	21 (3.7)
Moderate	238 (42.4)
Poor	303 (53.9)
Vascular invasion
Positive	153 (27.2)
Negative	409 (72.8)
Preoperative CEA
Positive	129 (23.0)
Negative	433 (77.0)
Preoperative CA19-9
Positive	62 (11.0)
Negative	500 (89.0)
Post-preoperative CEA elevation
Yes	184 (32.7)
No	378 (67.3)
Post-preoperative CA19-9 elevation
Yes	235 (41.8)
No	327 (58.2)
Adjuvant chemotherapy
Yes	522 (92.9)
No	40 (7.1)
Recurrence status
Yes	193 (34.3)
No	369 (65.7)
Survival status
Alive	338 (60.1)
Dead	224 (39.9)
Recurrence pattern
No recurrence	369 (65.7)
Peritoneal recurrence	79 (14.1)
Other recurrence sites	114 (20.3)

CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.